As sorafenib blocks the RAF/MEK/ERK pathway to inhibit tumor angiogenesis and induce apoptosis in HCC cells, the reactivation of ERK signaling confers acquired resistance to BRAF and MEK inhibitors [11, 15]. The gene discussed is MAP2K7; the disease is neoplasm.